Mar. 7 at 1:21 AM
$ABCL $IBRX
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Feb. 25, 2026 /PRNewswire/ -- Equity Insider News Commentary, The immuno-oncology market is forecast to grow from
$65.22 billion in 2025 to
$170.19 billion by 2032, fueled by checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines[1]. Five companies positioned at the forefront of this expansion include Oncolytics Biotech (NASDAQ: ONCY), ImmunityBio (NASDAQ: IBRX), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech (NASDAQ: BNTX), and Novocure (NASDAQ: NVCR).
The broader oncology market is projected to nearly triple from
$279.98 billion to
$748.17 billion by 2035, with North America commanding a 43% market share[2]. Targeted therapy remains the fastest-growing segment within the
$335.2 billion cancer drugs market projected for 2033, as personalized medicine reshapes treatment paradigms[3].
SOURCE: PR Newswire
This is called getting in on the ground floor.
